Compass Pathways PLC
F:5Y6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Compass Pathways PLC
F:5Y6
|
UK |
|
Panex Resources Inc
OTC:DBGF
|
MC |
|
T
|
TryHard Holdings Ltd
NASDAQ:THH
|
JP |
|
Signaux Girod SA
PAR:ALGIR
|
FR |
|
RITES Ltd
NSE:RITES
|
IN |
|
N
|
Northrop Grumman Corp
DUS:NTH
|
US |
|
A
|
American Electric Power Company Inc
XMUN:AEP
|
US |
|
M
|
Moshi Moshi Retail Corporation PCL
SET:MOSHI
|
TH |
|
Embassy Bancorp Inc
OTC:EMYB
|
US |
|
I
|
International Petroleum Corp
TSX:IPCO
|
CA |
|
N
|
Neuromeka Co Ltd
KOSDAQ:348340
|
KR |
Intrinsic Value
Is 5Y6 undervalued or overvalued?
See the intrinsic value estimate for 
Compass Pathways PLC and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
5Y6 looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with 5Y6’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Compass Pathways Does
Compass Pathways is a biotechnology company focused on developing psilocybin-based treatments for mental health conditions, especially difficult-to-treat depression. It is trying to turn a psychedelic compound into a controlled prescription medicine that can be used in a medical setting with therapist support.
- Headquarters
- United Kingdom UK
- Employees
- 156
- IPO date
- Sep 18, 2020
Earnings Waterfall
Compass Pathways PLC
The intrinsic value for Compass Pathways PLC (5Y6) under the Base Case is hidden EUR.
Compared with the current market price of 9.8 EUR, the stock appears hidden.